Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report
- PDF / 1,314,468 Bytes
- 5 Pages / 595.276 x 790.866 pts Page_size
- 44 Downloads / 190 Views
(2020) 14:185
CASE REPORT
Open Access
Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report Yudi Xiong1,2, Lei Yang1,2, Jing Dai1,2, Fuxiang Zhou1,2* and Yunfeng Zhou1,2*
Abstract Background: The incidence of angioimmunoblastic T-cell lymphoma is rare worldwide, and it has a poor prognosis. There is no proven or standard first-line therapy that works for the majority of patients with angioimmunoblastic T-cell lymphoma because of the rarity of this disease. The treatment and management are challenging for clinicians. Case presentation: This report presents the diagnosis and treatment of a 65-year-old Chinese man who presented with cough and lymph node swellings in the left axillary region. The patient was diagnosed with angioimmunoblastic T-cell lymphoma. He underwent eight cycles of chemotherapy with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) followed by TOMO radiotherapy (helical tomotherapy, a kind of radiotherapy for cancer treatment using spiral computed tomographic scanning). After treatment, the therapeutic effects were evaluated by magnetic resonance imaging and computed tomography about every 3 months. The patient recovered well with no sign of tumor recurrence and no obvious severe treatment-related adverse effects. Conclusion: This treatment experience indicates an essential role for the combination of radiation therapy with CHOP, which may have a better prognosis than treatments without radiation therapy. But challenges warrant further validation in prospective studies. Keywords: T-cell lymphoma, Angioimmunoblastic T-cell lymphoma, Chemotherapy, CHOP, TOMO radiotherapy
Background Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma that accounts for 1–2% of all people with non-Hodgkin lymphoma [1]. However, it is one of the most common types of peripheral T-cell lymphoma [2, 3]. It was first reported clinically in 1974 and characterized as a very aggressive disease associated with rash, pleural effusions, polyclonal hypergammaglobulinemia, ascites, and autoimmune phenomenon [4]. It has a poor * Correspondence: [email protected]; [email protected] 1 Hubei Cancer Clinical Study Center, Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital, Wuhan University, Wuhan, China Full list of author information is available at the end of the article
prognosis, with 5-year progression-free survival (PFS) being approximately 25% [5]. A review found only one of seven patients could survive longer than 3 years [6]. So far, because of the rarity of this disease, there is no proven or standard first-line therapy that works for the majority of patients with AITL. The patients are treated with a traditional non-Hodgkin lymphoma therapy or in clinical trials [7]. Here, in order to provide some information on its treatment, we report a case of a patient with AITL who was treated successfully with CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin, prednisone) in combination with tomothe
Data Loading...
